問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chung Shan Medical University Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

Division of Dermatology

更新時間：2023-09-19

魏正宗
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

魏正宗

List

124Cases

2019-09-01 - 2022-12-17

Phase II

An adaptive Phase 2 randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of multiple LOU064 doses in patients with moderate to severe Sjögren’s Syndrome (LOUiSSe)

  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    LOU064

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

藍忠亮
China Medical University Hospital

2020-12-31 - 2023-12-31

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects with Sjögren’s Syndrome (SS)

  • Condition/Disease

    Sjögren’s Syndrome (SS)

  • Test Drug

    VIB4920

Participate Sites
5Sites

Recruiting5Sites

2016-12-01 - 2018-12-31

Phase II

A Phase IIa, Randomized, Double blinded, Placebo-controlled, Dose-finding Study for Single-dose Administration of TLC599 in Patients with Osteoarthritis (OA) of Knee

  • Condition/Disease

    Osteoarthritis (OA) of Knee

  • Test Drug

    TLC599

Participate Sites
9Sites

Terminated8Sites

張棋楨
Taipei Medical University Hospital

2016-09-30 - 2019-12-31

Phase II

A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis

  • Condition/Disease

    Active psoriatic arthritis

  • Test Drug

    BI655066

Participate Sites
9Sites

Terminated7Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

黃春明
China Medical University Hospital-Taipei

未分科

2017-01-01 - 2020-06-30

Phase III

A Phase 3 Multicenter, Randomized, Double-blind,Placebo-controlled Study with an Open Label Extension to Evaluatethe Efficacy and Safety of KHK4827 in Subjects with Axial Spondyloarthritis

  • Condition/Disease

    Axial Spondyloarthritis

  • Test Drug

    KHK4827 (Brodalumab)

Participate Sites
13Sites

Terminated11Sites

羅淑芬
Linkou Chang Gung Medical Foundation

黃春明
China Medical University Hospital-Taipei

未分科

2008-04-01 - 2010-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-12-03 - 2020-08-10

Phase III

A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

  • Condition/Disease

    PSORIATIC ARTHRITIS

  • Test Drug

    XELJANZ XR

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2013-11-06 - 2017-07-31

Phase III

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE TNF INHIBITOR

  • Condition/Disease

    PSORIATIC ARTHRITIS

  • Test Drug

    Xeljanz

Participate Sites
5Sites

Terminated5Sites

藍忠亮
China Medical University Hospital

2013-09-04 - 2017-09-15

Phase III

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

  • Condition/Disease

    PSORIATIC ARTHRITIS

  • Test Drug

    Xeljanz

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2013-04-16 - 2016-08-18

Phase II

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)

  • Condition/Disease

    ANKYLOSING SPONDYLITIS

  • Test Drug

    Tofacitinib (CP-690550)

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

黃春明
China Medical University Hospital

Division of General Internal Medicine

1 9 10 11 12 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB